A higher-titer ANA raises the suspicion that something more systemic may be going on,’ said Amanda Mixon, PA-C.

This review in Food Science & Nutrition synthesizes evidence showing that walnuts (Juglans regia L.) exert potent antioxidant ...

Sacituzumab govitecan significantly improved survival outcomes for previously untreated, PD-L1-negative metastatic triple-negative breast cancer compared with chemotherapy, according to results from a ...

Angelina Labib, MD; Heather R. Gochnauer, MD; Lawrence F. Eichenfield, MD A 10-year-old girl with a history of allergic rhinitis presents to the dermatology clinic with a rash on her face that has ...

First clinical data disclosure for CB-011 highlights its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory ...

NASP data highlight reduction in disease burden among people living with uncontrolled goutGamifant (emapalumab) data showed response rates in ...

Incyte today announced the expansion of its Moments of Clarity program, which amplifies the voices of people living with chronic immune-mediated skin conditions. This year, the initiative introduces ...

Cardiff Oncology (CRDF) is a speculative buy with potential blockbuster gains ahead of its 2026 data readout. Read here for more analysis.

In two replicate Phase 3 studies, upadacitinib (RINVOQ ® ) achieved the co-primary endpoints of 50% reduction in Total Vitiligo Area Scoring Index (T-VASI 50) from baseline and 75% reduction in Facial ...

We have a very high response rate, very deep response rate, and very high MRD negativity rates,” said study presenter Marc S. Raab, MD.

Health Canada has granted a Notice of Compliance (NOC) for Enhertu® (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...